Overview
ALGS market data
Price History
ALGS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ALGS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Aligos Therapeutics Completes Enrollment Of HBeAg+ Patients In Its Phase 2 B-SUPREME Trial Of Pevifoscorvir Sodium To Treat Chronic Hepatitis B Virus InfectionBenzinga · Jul 13, 2026, 12:01 PM
Aligos Therapeutics Receives Upfront Payment Of $25M From Exclusive License Deal Of Pevifoscorvir Sodium In Greater China With Xiamen Amoytop; Pevifoscorvir Granted Breakthrough Therapy DesignationBenzinga · Jul 6, 2026, 8:10 PM
8-K filing — Aligos Therapeutics, Inc. (ALGS)SEC EDGAR · Jun 26, 2026, 8:02 PM
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45Benzinga · May 28, 2026, 5:18 PM
Aligos Therapeutics Reports 40% Of HBeAg+ Chronic HBV Patients Achieve HBsAg Reduction After 48 Weeks Of Pevifoscorvir SodiumBenzinga · May 27, 2026, 7:31 AM
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20Benzinga · May 21, 2026, 2:20 PM
Aligos Therapeutics To Present Ten Posters On Pevifoscorvir, ALG-170675 And ALG-055009 At EASL Congress 2026Benzinga · May 13, 2026, 6:39 AM